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enhances the practice of optometry than
60 units covering management. Conran
also called the Board's treatment of foreign-trained graduates a disgrace, alluding to the Board's past refusal to
accept foreign optometric training, and
its foot-dragging in creating a remedial
training course for foreign graduates
after being directed to do so by the
legislature. (See CRLR Vol. 10, Nos. 2
& 3 (Spring/Summer 1990) p. 113; Vol.
9, No. 4 (Fall 1989) p. 73; and Vol. 9,
No. 3 (Summer 1989) pp. 64-65 for
extensive background information.)
Conran concluded his remarks by
offering his assistance and encouraging
the Board to make constructive changes
before DCA or the legislature imposes
changes on the Board without regard to
its input. "You'd better get with it
quickly," observed Conran. Board members had no questions for Conran.
At its November meeting, the Board
elected the following officers for 1992:
Thomas R. Nagy, president; Pamela J.
Miller. vice president; and Julia Preisig,
secretary. Nagy and Miller are optometrists and Preisig is a public member
of the Board. Also, Bob Miller has been
reassigned to the Board to replace Steve
Martini as the Board's DCA legal
advisor.

FUTURE MEETINGS:
May 29-30 (location undecided).
BOARD OF PHARMACY
E.rerntil'e Officer: Patricia Harris
(9/6) 445-50/4

Pursuant to Business and Professions
Code section 4000 et seq., the Board of
Pharmacy grants licenses and permits
to pharmacists, pharmacies, drug manufacturers, wholesalers and sellers of hypodermic needles. It regulates all sales
of dangerous drugs, controlled substances and poisons. The Board is authorized to adopt regulations, which are
codified in Division 17, Title 16 of the
California Code of Regulations (CCR).
To enforce its regulations, the Board
employs full-time inspectors who investigate accusations and complaints
received by the Board. Investigations
may be conducted openly or covertly as
the situation demands.
The Board conducts fact-finding and
disciplinary hearings and is authorized
by law to suspend or revoke licenses or
permits for a variety of reasons, including professional misconduct and any
acts substantially related to the practice
of pharmacy.
The Board consists of ten members,
three of whom are public. The remain-
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ing members are pharmacists, five of
whom must be active practitioners. All
are appointed for four-year terms.

MAJOR PROJECTS:
Pharmacy Technician Regulations.
AB I 244 (Polanco) (Chapter 841, Statutes of 1991 ), which was signed into
law on October 11, permits a pharmacy
technician, as defined, to perform packaging, manipulative, repetitive, or other
nondiscretionary tasks while assisting,
and while under the direct supervision
of, a registered pharmacist. (See CRLR
Vol. 11, No. 4 (Fall 1991) pp. 105-06
for background information.) The Board
of Pharmacy is authorized to adopt regulations defining the functions which may
be performed by a pharmacy technician. In December, the Board published
notice of its intent to amend section
1717 (c) and adopt new sections 17931793. 7, Division 17, Title 16oftheCCR,
to define the qualifications and permissible duties of pharmacy technicians.
Existing section I 7 I 7(c) lists certain
duties which must be performed by a
pharmacist and those duties which may
be performed by non-licensed personnel, such as typing prescription labels
and requesting and receiving refill authorization subject to prior review by a
pharmacist. The Board proposes to incorporate portions of this section into
new sections 1793.1 and 1793.3. Specifically, proposed section 1793.1 would
list functions which only a pharmacist
may perform and which may not be
delegated to a pharmacy technician; section 1793.2 would identify the tasks
which a pharmacy technician may perform under the direct supervision and
control of a licensed pharmacist, including removing drugs from stock,
counting, pouring, or mixing pharmaceuticals. placing the products into a
container, affixing labels to containers,
packaging and repackaging; and proposed section 1793.3 would describe
and update tasks which may be performed by non-licensed personnel who
are not pharmacy technicians, to include
the entry of prescriptions into a computer record system.
Proposed section 1793.4 would establish registration requirements for
pharmacy technicians, and authorize the
Board to issue a certificate to an applicant who has met any of the following
requirements: has obtained at least an
associate of arts degree in a field of
study directly related to the duties performed by a pharmacy technician; has
completed a training course specified
by the Board; is eligible to take the
Board's pharmacist licensure exam; or
has one year's experience (a minimum

of 1,500 hours) performing the tasks of
a pharmacy technician while assisting a
pharmacist in the preparation of prescriptions in specified facilities. Section 1793.5 would specify the training
courses which are acceptable to the
Board in satisfaction of the requirement
in section 1793.4. Section 1793.6 would
establish requirements for pharmacies
employing technicians; in particular, it
clarifies that nonpharmacist personnel
must work under the direct supervision
of a registered pharmacist, the supervising pharmacist must be on the premises
at all times, and the pharmacist must
indicate that all prescriptions prepared
by a technician have been checked by
initialing the prescription label before
the medication is given to the patient.
The subsection also requires a technician to wear identification clearly identifying him/her as a technician.
The Board held an informational public hearing on the proposed pharmacy
technician regulations on November 12;
it was scheduled to hold a formal regulatory hearing on these regulations on
January 21.
Locked Storage and Emergency
Delivery Requirements for Medical
Device Retailers. Since July 1991, the
Board of Pharmacy has licensed medical device retailers (MDRs) as a separate class. MDRs are non-pharmacy
firms that may dispense, upon prescription, "dangerous devices" such as hypodermic syringes and other items that
are marked by the manufacturer as available upon prescription only. Each retail
site of an MOR must have a Boardlicensed individual designated as "in
charge." This individual may be a pharmacist or an "exemptee," a separatelylicensed individual authorized to dispense dangerous devices. The Board
recently proposed the adoption of new
sections 1748.1 and 1748.2, Title 16 of
the CCR, regarding the proper storage
of dangerous devices at MOR retail sites
and the delivery of devices to patients
after hours or in emergency situations.
Proposed section 1748.1 would provide that an MOR may use locked storage (a lock box or locked area) for the
emergency dispensing of dangerous devices. Locked storage may be installed
or placed in a service vehicle of the
MOR for purposes of delivery, set-up,
or after-hours emergency service of dangerous devices to patients having prescriptions on file for the dangerous device. No hypodermic needles or syringes
may be stored in this locked storage.
Section 1748.1 would also provide that
dangerous devices shall be furnished
from the locked storage only upon the
oral or written authorization of an
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exemptee to an employee of the MOR
who operates the service vehicle; the
service vehicle and the locked storage
contained therein shall be locked at all
times: a current inventory and record of
all dangerous devices placed into and
furnished from the locked storage shall
be maintained by the MOR for three
years; within 72 hours of furnishing a
dangerous device from the emergency
storage, the exemptee shall be responsible for checking the contents of the
locked storage and noting the dangerous devices furnished on the inventory;
and the exemptee shall be responsible
for checking the contents of the locked
storage on a weekly basis.
Proposed section 1748.2 would permit an MOR to keep a dangerous device
in a retail area of the premises during
the absence of an exemptee. if the device is of sufficient size and weight as
to make removal "difficult." The Board
was scheduled to conduct a public hearing on this proposal on January 22.
Board Delays Patient Consultation
Regulations Again. In August 1990, the
Office of Administrative Law (OAL)
approved the Board's adoption of new
sections 1707. I and 1707 .2. Title 16 of
the CCR, which require pharmacists to
maintain patient medication profiles for
all ongoing patient-consumers and provide an oral consultation to each patient
or patient's agent, with specified exceptions. The oral consultation requirement
was originally scheduled to take effect
on March I, 1991. However, on January 11, 1991, OAL approved the Board's
request to delay the effective date until
January I, 1992. (See CRLR Vol. IL
No. 2 (Spring 1991) p. 98 for background information.) The Board delayed
the implementation to (I) provide pharmacists with additional time to prepare
for and phase in the changes to pharmacy practice mandated by sections
1707.1 and 1707.2; (2) permit a more
assistive resolution to the pharmacy
technician issue; and (3) amend Board
regulations to foster spatial arrangements in pharmacies that are conducive
to privacy for performing patient consultation. However, at this writing, the
Board has not yet proposed regulations
concerning spatial arrangements. and
only recently initiated its proceeding to
adopt technician regulations (see supra).
At its October 16 meeting, the Board
heard a report from its Patient Consultation Implementation Committee,
which was formed to hear concerns from
and provide feedback to interested parties regarding the new regulations. Committee Chair Gilbert Castillo informed
the Board that the Committee had received several requests for delays or

waivers of the oral consultation requirement from affected pharmacies. He
stated that the Committee's recommendation was to proceed with implementation as scheduled.
The Board then entertained testimony
from representatives of several large
pharmacy chains, HMOs, and trade associations, including Longs Drugs, Kaiser Permanente, and the California Retailers Association. These companies
complained that the imposition of such
broad new duties on the entire industry
may lead to selective compliance (depending on the adequacy of the
pharmacy's staffing), inconsistency, and
potential liability problems. Further, and
after eighteen months' lead time, these
companies argued that they were unprepared to comply on January I without the use of pharmacy technicians,
and this new category of pharmacy employee is not expected to be authorized
by regulations until at least April. The
representatives also implied that if the
regulations went into effect as scheduled, they may initiate litigation to challenge them.
Board members pointed out that the
effective date had already been delayed
once in response to these concerns, and
that it had been apparent for some time
that the regulations providing for technicians would not be in place before the
consultation requirement became effective. The Board voted 3-2 to proceed
with implementation on January I.
Notwithstanding that action, the
Board continued to receive requests to
once again delay implementation of the
oral consultation requirement. Board
President William Tan called a special
meeting on December 4 to reconsider
the Board's previous vote. At that meeting, industry representatives again
claimed to be unprepared to comply
with the regulations without additional
staff and expressed concern that delivery of medications might be delayed if
the Board required them to comply
with the oral consultation rule on January I. Finally, the Board voted to delay the effective date until November
I, 1992.
Upon consultation with OAL, the
Board will adopt a two-part procedure
to accomplish the delay: (I) it will suspend the regulations as an emergency
action for the 120 days allowed for such
actions under the Administrative Procedure Act (Government Code section
11346.l(e)); and(2) it will proceed with
an ordinary rulemaking action to change
the effective date to November I. The
Board was scheduled to hold public
hearings on the formal regulatory action at its March 18 meeting; at this
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writing, the emergency suspension
awaits OAL approval.
Partial Filling of Schedule II Prescriptions. At its October 16 meeting,
the Board held a public hearing on its
proposed adoption of section 1745, Title
16 of the CCR. As originally proposed,
section 1745 would allow partial filling
of Schedule II controlled substance prescriptions for terminally ill patients who
are in chronic pain, under certain circumstances. (See CRLR Vol. 11. No. 4
(Fall 1991) p. I 05 for background information.) During the hearing, the
Board amended the text to add new
language which would also allow partial filling when the prescription is for
an inpatient of a skilled nursing facility.
The Board released the modified language for a 15-day comment period ending on December 24, and was expected
to adopt the new language at its January
meeting.
Federal Policy Guide Regarding
New Drug Repacking. In a July 16 letter to the federal Food and Drug Administration (FDA), the Board sought
clarification of FDA's Compliance
Policy Guide 7 l 32c.06. (See CRLR Vol.
11, No. 4 (Fall 1991) p. !04 for background information.) The guide defines
FDA policy regarding drug manipulations which are approved if conducted
within the practice of pharmacy, and
those manipulations which constitute
"manufacturing" and require separate
FDA approval. Although FDA has not
formally replied to the Board, its district supervisor for southern California
forwarded a number of documents to
the Board on this subject. The documents indicate that FDA is working on
the issue with the National Association
of Boards of Pharmacy (NABP). It is
NABP's position that compounding and
manufacturing are distinct activities, and
that compounding is a proper part of the
practice of pharmacy. Further, NABP
opined that it is beyond the scope of
FDA's authority for it to intrude "upon
the state regulation of pharmacy practice." At its October meeting, the Board
essentially agreed with NABP's position, and noted that clarification is still
needed as to whether the "breaking down
of bulk drugs for prescription or known
need" constitutes manufacturing. The
Board voted to send another letter to
FDA expressing its concern and seeking such clarification.
Part-Time Pharmacists-in-Charge.
At its October meeting, the Board continued its discussion of possible amendments to section 1709. I, Title 16 of the
CCR, which governs the designation of
the pharmacist-in-charge at each pharmacy and prohibits a pharmacist from
91
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acting as pharmacist-in-charge at more
than one pharmacy. (See CRLR Vol. 11,
No.4(Fall 199l)p.105forbackground
information.) In response to inquiries,
the Board decided to clarify one narrow
exception to that prohibition. At the
meeting, the Board agreed on a proposed amendment that would allow a
pharmacist to be pharmacist-in-charge
at two pharmacies when each such pharmacy employs only that pharmacist and
is not open at any time when the other
pharmacy for which that pharmacist is
the pharmacist-in-charge is open. The
Board anticipated publishing notice of
this amendment in January and holding
a public hearing at its March meeting.
Regulatory Update. The following
is a status update on regulatory changes
considered and approved by the Board
in recent months (see CRLR Vol. 11,
No. 4 (Fall 1991) p. 105; Vol. 11, No. 3
(Summer 1991) p. 102; and Vol. 11, No.
2 (Spring 1991) p. 98 for background
information):
-Compounding for Office Use. The
Board has adopted proposed new section 1716.1, which defines the quantity
of compounded medication which a
pharmacist may furnish to a prescriber
for office use under Business and Professions Code section 4046(c)(l), and
proposed new section 1716.2, which
specifies the minimum types of records
that pharmacies must keep when they
furnish compounded medication to prescribers in quantities larger than required
for the prescriber's immediate office use
or when a pharmacy compounds medication for future furnishing. At this writing, the proposed sections await review
and approval by OAL.
-Minimum Standards for Drug
Wholesalers. At its May meeting, the
Board adopted proposed amendments
to section 1780, regarding minimum
standards for drug wholesalers. At this
writing, the proposed amendments await
review and approval by OAL.
LEGISLATION:
AB 2070 (Isenberg), as amended
August 19, would generally make it unlawful for specified healing arts licensees to refer a person to any laboratory,
pharmacy, clinic, or health care facility
solely because the licensee has an ownership interest in the facility. However,
a licensee could make those referrals if
the person referred is the licensee's patient of record, there is no alternative
provider or facility available, and the
licensee certifies that to delay or forego
the referral would cause an unneeded
health risk to the patient. This two-year
bill is pending in the Senate Rules
Committee.
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SB 664 (Calderon) would prohibit
pharmacists, among others, from charging, billing, or otherwise soliciting payment from any patient, client, customer,
or third-party payor for any clinical laboratory test or service if the test or service was not actually rendered by that
person or under his/her direct supervision, except as specified. This bill is
pending in the Senate Business and Professions Committee.
AB 1226 (Hunter) would change
the standard to be applied by the Director of the Department of Health Services in establishing a formulary of generic drug types and drug products, to
require him/her to identify those generic drug types and drug products
which, if substituted by a pharmacist
for a drug product described by the prescriber by its trade or brand name, may
pose a threat to the health and safety
of patients. This bill is pending in the
Assembly Health Committee.
SB /033 (Marks) would permit pharmacists to manufacture, measure, fit to
the patient, sell, and repair medical devices without regard to whether they
bear a specified legend relating to a
federal prohibition against dispensing
without a prescription. This bill is pending in the Senate Business and Professions Committee.
AB 855 (Hunter), as amended July
16, would require a pharmacist to obtain a patient's consent prior to filling a
prescription order for a drug product
prescribed by its trade or brand name
with a substitute drug product. This twoyear bill is pending in the Senate Business and Professions Committee.
SB 917(Kopp), as amended June 11,
would require certain health care service plans that propose to offer a pharmacy benefit or change its relationship
with pharmacy providers to give written or published notice to pharmacy service providers of the plan's proposal,
and give those providers an opportunity
to submit a bid to participate in the
plan's panel of providers on the terms
proposed. This bill is pending at the
Assembly desk.
AB 8/9 (Speier). Existing law provides that it is not unlawful for prescribed licensed health professionals to
refer a person to a laboratory, pharmacy,
clinic, or health care facility solely because the licensee has a proprietary interest or co-ownership in the facility.
This bill would instead provide that,
subject to specified exceptions, it is unlawful for these licensed health professionals to refer a person to any laboratory, pharmacy, clinic, or health care
facility which is owned in whole or in
part by the licensee or in which the

licensee has a proprietary interest; the
bill would also provide that disclosure
of the ownership or proprietary interest
does not exempt the licensee from the
prohibition. This bill is pending in the
Assembly Health Committee.
Future Legislation. At this writing,
the Board is drafting three legislative
proposals for the 1992 session. First,
the Board may seek to repeal a portion
of Business and Professions Code section 4038 which exempts pharmacies
and state-licensed drug manufacturers
from licensure requirements as wholesalers. The federal Prescription Drug
Marketing Act requires state licensure
of any firm that wholesales prescription
drugs; thus, California's exemption is
in conflict with the federal law.
Second, the Board may seek to correct an erroneous reference in Business
and Professions Code section 4033,
which occurred as a result of sections
being renumbered in 1980.
Third, the Board may propose an
amendment to Business and Professions
Code section 4366 to allow the Board to
recover its investigative and other enforcement costs from a disciplined licensee in cases other than drug diversion, as is currently permitted. The Board
wants broad discretion to recover its
costs in other cases-e.g., filling unauthorized prescriptions or professional
misconduct.
The California Pharmacists' Association (CPA) has announced its fourpart legislative program for 1992. First,
CPA will seek legislation aimed at outof-state mail order pharmacies. According to CPA, certain health care insurers
and other plans currently encourage the
use of out-of-state pharmacies by offering different co-payments or deductibles
for drugs ordered from those pharmacies. CPA believes this system discriminates against California pharmacies and
sends California dollars out-of-state,
instead of supporting the local economy.
CPA may seek legislation that would
prohibit indemnity health care plans
from providing unequal co-payment and
deductible plans for out-of-state mail
order pharmacy benefits.
Second, CPA supports a pending congressional resolution which would ask
FDA to establish a transitional class of
drugs between the existing prescription
and over-the-counter classes. Included
in this transitional category would be
drugs that had been prescription-only,
but are destined for reclassification by
FDA as over-the-counter. Pharmacists
would be allowed to dispense these
drugs without a physician's authorization, but would be required to consult
with the patient on the use of the drug.
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Third. CPA supports SB 917 (Kopp).
a two-year bill which would require certain health care service plans. when offering new pharmacy benefits in an area.
to notify all pharmacies in the area and
take bids from all such pharmacies (see

supra).
Finally. CPA may seek legislation to
provide that it is a felony offense for
any person who. in order to obtain any
drug. falsely represents him/herself to
be a physician or other person who may
lawfully prescribe the drug. or falsely
represents that he/she is acting on behalf of a person who may lawfully prescribe the drug, in a telephone commu;;ication with a registered pharmacist:
currently. such an act constitutes a
misdemeanor.

RECENT MEETINGS:
At its October 16 meeting, the Board
once again discussed the possibility of
adopting regulations to better control
fee arrangements between physicians
and home health agencies. (See CRLR
Vol. 11, No. 4 (Fall 1991) p. 104: Vol.
11, No. 3 (Summer 1991) p. IOI; and
Vol. 11, No. 2 (Spring 1991) p. 97 for
background information.) Specifically,
the Board has been considering regulations that would require the disclosure
of contracts between home health care
companies and health care consultants
and which would provide the Board with
authority to access the financial records
of pharmacies. Department of Consumer
Affairs (DCA) legal counsel Robert
Miller suggested that the Board work
with the DCA Director, who has broad
investigory powers to obtain such
records; the Board took no formal action at the October meeting.
Also at its October meeting, the
Board discussed the final rule adopted
by the federal Nuclear Regulatory Commission (NRC) which requires medical
licensees to establish quality management programs in an effort to reduce
misadministrations of radiopharmaceuticals. (See CRLR Vol. 11, No. 3
(Summer 1991) p. IO I for background
information.) The Board had previously
opposed such a requirement as unnecessary in light of existing state regulations, and not warranted by the data
compiled by the NRC. Despite this and
other opposition, the NRC adopted the
rule. The Board heard testimony from
radiopharmacists who believe the rule
places an enormous burden on small
businesses without adding any safety or
other benefit to the public beyond what
is already in place. The Board agreed
to send another letter to the NRC requesting that the Commission reconsider the rule.

The Board also discussed a letter
from Deputy Attorney General Edward
G. Weil advising the Board that the state
Department of Justice has received numerous complaints that pharmacists are
not providing the FDA-required patient
package insert (PPI) when dispensing
conjugated estrogens. Mr. Weil recommended that the Board notify its Iicensees of their potential liability not only
under federal law. but for civil penaltie,
under Proposition 65 when the PP! is
not provided. Propo~ition 65. the Safe
Drinking Water and Toxics Enforcement
Act of 1986. provides that '"no person in
the course of doing business sh al I knowingly and intentionally expose any individual to a chemical known to the State
of California to cause cancer. birth defects or reproductive harm." without
providing a ""clear and reasonable warning." Proposition 65 applies to comumer
product~ in general, and to prescription
drugs: in 1987. the state determined that
conjugated estrogens are a chemical
known to cause cancer under Proposition 65. The Board agreed to publish a
warning to licensees in its next newsletter. Board member Robert Toomajian
noted that in light of the upcoming oral
consultation requirement (see supra
MAJOR PROJECTS), pharmac1'1s
should be notified of other prescnption
drugs that are known to cause cancer.
Deputy Attorney General Bill Marcus
opined that, to his knowledge, conJugated estrogens are the only drug identified by the state as cancer-causing thus
far in its Proposition 65 implementation
process.

FUTURE MEETINGS:
May 27-28 in Sacramento.
July 29-30 in San Francisco

BOARD OF REGISTRATION FOR
PROFESSIONAL ENGINEERS
AND LAND SURVEYORS
Executil·e Officer: Darlene Stroup
(916) 920-7466

The Board of Registration for Professional Engineers and Land Surveyors (PELS) regulates the practice of engineering and land surveying through
its administration of the Professional
Engineers Act, sections 6700 through
6799 of the Business and Professions
Code. and the Professional Land Surveyors' Act, sections 8700 through
8805 of the Business and Professions
Code. The Board's regulations are
found in Division 5, Title 16 of the
California Code of Regulations (CCR).

The California Regulatory Law Reporter Vol. 12, No. 1 (Winter 1992)

The basic functions of the Board are
to conduct examinations. issue certific,1tes, registrations. and/or licenses, and
appropriately channel complaints
against registrants/licensees. The Board
1s add1t1onally empowered to suspend
or revoke registrations/licenses. The
Board considers the proposed deci~1ons
of administrative law Judges who hear
appeals of applicanb who are denied a
registrat1on/1Icense, and those who have
had their registration/license suspended
or revoked for violations.
The Board consists of thirteen members: seven public members, one licensed land surveyor, four registered
Practice Act engineers and one Title Act
engineer. Eleven of the members are
appointed by the Governor for fouryear terms which expire on a staggered
basis. One public member 1s appointed
by the Speaker of the Assembly and one
by the Senate Rules Committee.
The Board has established four standing committees and appoints other special committees as needed. The four
standing committees are Administration,
Enforcement. Examination/Qualifications, and Legislation. The committees
function in an advisory capacity unless
specifically authorized to make binding
decisions by the Board.
Professional engineers are registered
through the three Practice Act categories of civil, electrical, and mechanical
engineering under section 6730 of the
Business and Professions Code. The
Title Act categories of agricultural.
chemical, control system, corrosion, fire
protection, industrial. manufacturing,
metallurgical, nuclear, petroleum, quality, safety, and traffic engineering are
registered under section 6732 of the
Business and Professions Code.
Structural engineering and geotechrncal engineering are authorities
linked to the civil Practice Act and require an additional examination after
qualification as a civil engineer.
Board members and industry representatives expressed sorrow at the October 12 death of Board member
Clarence E. (Bill) Mackey. In December, Governor Wilson appointed David
J. Slawson as the Board's land surveyor
member. Slawson, the president of a
civil engineering firm, replaces fo1mer
Board member James Dorsey. The Governor also appointed Mim Scott to the
Board as a public member. Scott, a senior vice-president of a master-planned
community developer. fills the seat of
former Board member Robert
Thornberg. Finally, the Senate Rules
Committee reappointed public member
Sharon Reid to the Board for her final
four-year term.
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